

# Christine Y Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6008758/publications.pdf>

Version: 2024-02-01

130  
papers

2,787  
citations

218677

26  
h-index

223800

46  
g-index

131  
all docs

131  
docs citations

131  
times ranked

4199  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type. <i>Journal of Personalized Medicine</i> , 2022, 12, 1146.	2.5	3
2	Experiences of health care costs among people with employer-sponsored insurance and bipolar disorder. <i>Journal of Affective Disorders</i> , 2021, 281, 41-50.	4.1	7
3	The ethics of grandfather clauses in healthcare resource allocation. <i>Bioethics</i> , 2021, 35, 151-160.	1.4	2
4	Integrating Stakeholder Engagement With Claims-Based Research on Health Insurance Design and Bipolar Disorder. <i>Psychiatric Services</i> , 2021, 72, 186-194.	2.0	4
5	Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. <i>Genetics in Medicine</i> , 2021, 23, 1366-1371.	2.4	16
6	Response to "Black Box Warning Did Not Cause Increased Suicides": <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 98-101.	2.4	1
7	Out-of-Pocket Spending Inequity Among High-Deductible Health Plan Members with Bipolar Disorder. <i>Journal of General Internal Medicine</i> , 2021, , 1.	2.6	1
8	Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. <i>Genetics in Medicine</i> , 2021, 23, 1689-1696.	2.4	17
9	Genetic variants of <i>PEAR1</i> and ischemic clinical outcomes in coronary artery disease patients: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2021, 22, 641-648.	1.3	3
10	Weighing the Association Between BMI Change and Suicide Mortality. <i>Psychiatric Services</i> , 2021, 72, 920-925.	2.0	5
11	Impact of High-Deductible Health Plans on Medication Use Among Individuals With Bipolar Disorder. <i>Psychiatric Services</i> , 2021, 72, 926-934.	2.0	1
12	Serious Suicide Attempts and Risk of Suicide Death. <i>Crisis</i> , 2021, 42, 343-350.	1.2	4
13	Integrating Patient-Reported Outcomes Into Clinical Genetic Testing for Familial Hypercholesterolemia. <i>Journal of Patient-centered Research and Reviews</i> , 2021, 8, 336-339.	0.9	0
14	Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 1284.	2.5	6
15	Genomic testing is best integrated into clinical practice when it is actionable. <i>Personalized Medicine</i> , 2020, 17, 5-8.	1.5	8
16	The case for implementing sustainable routine, population-level genomic reanalysis. <i>Genetics in Medicine</i> , 2020, 22, 815-816.	2.4	11
17	When should genomic and exome sequencing be implemented in newborns? A call for an update to newborn screening guidelines. <i>Genetics in Medicine</i> , 2020, 22, 809-810.	2.4	4
18	Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders. <i>General Hospital Psychiatry</i> , 2020, 62, 21-27.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Ending the Diagnostic Odyssey—Is Whole-Genome Sequencing the Answer?. <i>JAMA Pediatrics</i> , 2020, 174, 821.	6.2	39
20	A Qualitative Study to Develop a Privacy and Nondiscrimination Best Practice Framework for Personalized Wellness Programs. <i>Journal of Personalized Medicine</i> , 2020, 10, 264.	2.5	7
21	Increases in Suicide Deaths Among Adolescents and Young Adults Following US Food and Drug Administration Antidepressant Boxed Warnings and Declines in Depression Care. <i>Psychiatric Research and Clinical Practice</i> , 2020, 2, 43-52.	2.4	8
22	Association Between Switching to a High-Deductible Health Plan and Major Cardiovascular Outcomes. <i>JAMA Network Open</i> , 2020, 3, e208939.	5.9	15
23	Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. <i>BMJ Open</i> , 2020, 10, e033427.	1.9	14
24	Exploring African American community perspectives about genomic medicine research: A literature review. <i>SAGE Open Medicine</i> , 2020, 8, 205031212090174.	1.8	2
25	Substance use disorders and risk of suicide in a general US population: a case control study. <i>Addiction Science &amp; Clinical Practice</i> , 2020, 15, 14.	2.6	76
26	A Global Review on the Utility of Genetic Testing for Familial Hypercholesterolemia. <i>Journal of Personalized Medicine</i> , 2020, 10, 23.	2.5	11
27	What motivates the sharing of consumer-generated genomic information?. <i>SAGE Open Medicine</i> , 2020, 8, 205031212091540.	1.8	5
28	Effect of high-deductible insurance on health care use in bipolar disorder. <i>American Journal of Managed Care</i> , 2020, 26, 248-255.	1.1	10
29	Pharmacoepidemiological Approaches in Health Care. , 2020, , 171-202.		0
30	Variation in patterns of health care before suicide: A population case-control study. <i>Preventive Medicine</i> , 2019, 127, 105796.	3.4	70
31	The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 867-877.	1.2	5
32	Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review. <i>Journal of Personalized Medicine</i> , 2019, 9, 32.	2.5	20
33	Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	3
34	Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. <i>Journal of Personalized Medicine</i> , 2019, 9, 28.	2.5	6
35	Impact of ICD-10-CM Transition on Mental Health Diagnoses Recording. <i>EGEMS (Washington, DC)</i> , 2019, 7, 14.	2.0	20
36	Diagnosed Mental Health Conditions and Risk of Suicide Mortality. <i>Psychiatric Services</i> , 2019, 70, 750-757.	2.0	51

#	ARTICLE	IF	CITATIONS
37	Direct-to-Consumer Genetic Testing Data Privacy: Key Concerns and Recommendations Based on Consumer Perspectives. <i>Journal of Personalized Medicine</i> , 2019, 9, 25.	2.5	24
38	Direct-to-Consumer Genetic Testing and Potential Loopholes in Protecting Consumer Privacy and Nondiscrimination. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1869.	7.4	28
39	Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States. <i>Journal of Personalized Medicine</i> , 2019, 9, 9.	2.5	13
40	The Mediating Effect of Sleep Disturbance on the Relationship Between Nonmalignant Chronic Pain and Suicide Death. <i>Pain Practice</i> , 2019, 19, 382-389.	1.9	16
41	Long-Term Patterns of Oral Anticancer Agent Adoption, Duration, and Switching in Patients With CML. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1166-1172.	4.9	10
42	Cost burden of hepatitis C virus treatment in commercially insured patients. <i>American Journal of Managed Care</i> , 2019, 25, e379-e387.	1.1	5
43	Influence of Sleep Stage on LH Pulse Initiation in the Normal Late Follicular Phase and in Polycystic Ovary Syndrome. <i>Neuroendocrinology</i> , 2018, 107, 60-72.	2.5	11
44	Counter-Point. <i>Medical Care</i> , 2018, 56, 382-383.	2.4	5
45	Near Real-time Surveillance for Consequences of Health Policies Using Sequential Analysis. <i>Medical Care</i> , 2018, 56, 365-372.	2.4	9
46	General Medical, Mental Health, and Demographic Risk Factors Associated With Suicide by Firearm Compared With Other Means. <i>Psychiatric Services</i> , 2018, 69, 677-684.	2.0	22
47	Effect of High-Deductible Insurance on High-Acuity Outcomes in Diabetes: A Natural Experiment for Translation in Diabetes (NEXT-D) Study. <i>Diabetes Care</i> , 2018, 41, 940-948.	8.6	44
48	Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. <i>Genetics in Medicine</i> , 2018, 20, 1544-1553.	2.4	25
49	Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016). <i>Breast</i> , 2018, 38, 7-13.	2.2	23
50	State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015. <i>Value in Health</i> , 2018, 21, 692-697.	0.3	13
51	Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014). <i>British Journal of Cancer</i> , 2018, 118, 441-447.	6.4	13
52	Dermatologic Conditions and Risk of Suicide: A Case-Control Study. <i>Psychosomatics</i> , 2018, 59, 58-61.	2.5	10
53	A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. <i>Genetics in Medicine</i> , 2018, 20, 390-396.	2.4	20
54	Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. <i>Journal of Clinical Oncology</i> , 2018, 36, 1121-1127.	1.6	70

#	ARTICLE	IF	CITATIONS
55	Use of assisted reproductive technologies before and after the Artificial Reproduction Act in Taiwan. PLoS ONE, 2018, 13, e0206208.	2.5	10
56	High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes. Annals of Internal Medicine, 2018, 169, 845.	3.9	41
57	Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. Journal of Personalized Medicine, 2018, 8, 19.	2.5	30
58	Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan's National Health Insurance Research Database. PLoS ONE, 2018, 13, e0204206.	2.5	24
59	The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies. Journal of Personalized Medicine, 2018, 8, 32.	2.5	4
60	Comment on "Measuring the impact of medicines regulatory interventions" systematic review and methodological considerations by Goedecke <i>et al</i> .. British Journal of Clinical Pharmacology, 2018, 84, 2167-2168.	2.4	2
61	Counter-Point. Medical Care, 2018, 56, 384-390.	2.4	5
62	Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. Breast Cancer Research and Treatment, 2018, 171, 235-242.	2.5	10
63	Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease. Pharmacoepidemiology and Drug Safety, 2018, 27, 872-877.	1.9	2
64	Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016). Breast Cancer Research and Treatment, 2018, 171, 151-159.	2.5	20
65	Geographic Variations and Time Trends in Cancer Treatments in Taiwan. BMC Public Health, 2018, 18, 89.	2.9	5
66	Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. Breast Cancer Research and Treatment, 2018, 171, 449-459.	2.5	20
67	Access to High Cost Medicines: An Overview. , 2018, , 1-10.		0
68	Diabetes Outpatient Care and Acute Complications Before and After High-Deductible Insurance Enrollment. JAMA Internal Medicine, 2017, 177, 358.	5.1	73
69	Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk. Journal of Comparative Effectiveness Research, 2017, 6, 25-32.	1.4	13
70	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. BMJ Open, 2017, 7, e014439.	1.9	15
71	Major Physical Health Conditions and Risk of Suicide. American Journal of Preventive Medicine, 2017, 53, 308-315.	3.0	182
72	10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ Open, 2017, 7, e014150.	1.9	34

#	ARTICLE	IF	CITATIONS
73	Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans. <i>JAMA Cardiology</i> , 2017, 2, 1164.	6.1	22
74	Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer. <i>Value in Health</i> , 2017, 20, 1345-1354.	0.3	2
75	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. <i>Drug Safety</i> , 2017, 40, 91-100.	3.2	0
76	Trend and geographic analysis of the prevalence of dengue in Taiwan, 2010–2015. <i>International Journal of Infectious Diseases</i> , 2017, 54, 43-49.	3.3	36
77	Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients. <i>Journal of Personalized Medicine</i> , 2017, 7, 17.	2.5	7
78	Association between the 2012 Health and Social Care Act and specialist visits and hospitalisations in England: A controlled interrupted time series analysis. <i>PLoS Medicine</i> , 2017, 14, e1002427.	8.4	22
79	Payer Decision-Making for Pharmacogenetic Tests: Preliminary Results. <i>Journal of Patient-centered Research and Reviews</i> , 2017, 4, 170-171.	0.9	1
80	Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 798-814.	1.9	8
81	Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. <i>BMJ Open</i> , 2016, 6, e008671.	1.9	24
82	Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study. <i>BMJ Open</i> , 2016, 6, e011322.	1.9	14
83	National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1425-1435.	2.6	4
84	Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan. <i>BMJ Open</i> , 2016, 6, e010706.	1.9	2
85	Racial-Ethnic Differences in Psychiatric Diagnoses and Treatment Across 11 Health Care Systems in the Mental Health Research Network. <i>Psychiatric Services</i> , 2016, 67, 749-757.	2.0	95
86	Missing clinical and behavioral health data in a large electronic health record (EHR) system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 1143-1149.	4.4	112
87	Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 333-340.	2.5	8
88	Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group. <i>Value in Health</i> , 2016, 19, 577-587.	0.3	31
89	Economic evaluation of whole-genome sequencing in healthy individuals: what can we learn from CEAs of whole-body CT screening?. <i>Genetics in Medicine</i> , 2016, 18, 103-104.	2.4	3
90	Insurance Coverage Policies for Guideline-Recommended Genetic Testing for Targeted Cancer Therapies: Preliminary Results. <i>Journal of Patient-centered Research and Reviews</i> , 2016, 3, 193-194.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1026-1035.	1.9	8
92	Racial/Ethnic Differences in Health Care Visits Made Before Suicide Attempt Across the United States. <i>Medical Care</i> , 2015, 53, 430-435.	2.4	89
93	Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. <i>PLoS ONE</i> , 2015, 10, e0140002.	2.5	183
94	Net Clinical Benefit of Oral Anticoagulants: A Multiple Criteria Decision Analysis. <i>PLoS ONE</i> , 2015, 10, e0124806.	2.5	19
95	Barriers to access and use of high cost medicines: A review. <i>Health Policy and Technology</i> , 2015, 4, 191-214.	2.5	23
96	The evolution of Taiwan's National Health Insurance drug reimbursement scheme. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2015, 23, 15.	2.0	24
97	How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?. <i>Clinical Therapeutics</i> , 2015, 37, 1420-1432.e1.	2.5	10
98	Restricting access to florbetapir: Medicare coverage criteria for diagnostics and drugs are inconsistent: Table 1. <i>BMJ, The</i> , 2015, 351, h3333.	6.0	6
99	Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. <i>Clinical Therapeutics</i> , 2015, 37, 1280-1291.	2.5	15
100	Can Genomic Medicine Improve Financial Sustainability of Health Systems?. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 71-77.	3.8	8
101	Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, 7.	2.4	7
102	Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, 15.	2.4	9
103	Policies and Programs to Facilitate Access to Targeted Cancer Therapies in Thailand. <i>PLoS ONE</i> , 2015, 10, e0119945.	2.5	21
104	Authors' reply to Olfson and Schoenbaum, Nardo, Bartlett, Moore, Case, Gotzsche, and Barber and colleagues. <i>BMJ, The</i> , 2014, 349, g5722-g5722.	6.0	1
105	Authors' reply to Mosholder and colleagues. <i>BMJ, The</i> , 2014, 349, g6516-g6516.	6.0	1
106	Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. <i>BMJ, The</i> , 2014, 348, g3596-g3596.	6.0	172
107	How complete are E-codes in commercial plan claims databases?. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 218-220.	1.9	34
108	Uncertainties in real-world decisions on medical technologies. <i>International Journal of Clinical Practice</i> , 2014, 68, 936-940.	1.7	9

#	ARTICLE	IF	CITATIONS
109	Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: An interrupted time series study. <i>Health Policy</i> , 2014, 116, 196-205.	3.0	19
110	Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?. <i>Breast</i> , 2013, 22, 482-487.	2.2	20
111	Changes in use of antidiabetic medications following price regulations in China (1999-2009). <i>Journal of Pharmaceutical Health Services Research</i> , 2013, 4, 3-11.	0.6	10
112	New users of antidepressant medications: first episode duration and predictors of discontinuation. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 65-71.	1.9	26
113	Taking on glaucoma care as an interprofessional team. <i>Canadian Journal of Ophthalmology</i> , 2011, 46, 465-467.	0.7	1
114	Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 223-228.	5.0	74
115	Association Between Prior Authorization for Medications and Health Service Use by Medicaid Patients With Bipolar Disorder. <i>Psychiatric Services</i> , 2011, 62, 186-193.	2.0	33
116	The Importance of High-Quality Evidence of the Long-Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 27-29.	4.7	7
117	Determinants of patient-reported medication errors: a comparison among seven countries. <i>International Journal of Clinical Practice</i> , 2011, 65, 733-740.	1.7	31
118	Impact of Prior Authorization on the Use and Costs of Lipid-Lowering Medications Among Michigan and Indiana Dual Enrollees in Medicaid and Medicare: Results of a Longitudinal, Population-Based Study. <i>Clinical Therapeutics</i> , 2011, 33, 135-144.	2.5	31
119	Unintended Impacts of a Medicaid Prior Authorization Policy on Access to Medications for Bipolar Illness. <i>Medical Care</i> , 2010, 48, 4-9.	2.4	68
120	Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: Results of a longitudinal, population-based study. <i>Clinical Therapeutics</i> , 2010, 32, 729-741.	2.5	30
121	Towards integrated care: Australia's new model of care for patients with glaucoma. <i>Medical Journal of Australia</i> , 2010, 193, 200-201.	1.7	7
122	Prior Authorization for Antidepressants in Medicaid. <i>Archives of Internal Medicine</i> , 2009, 169, 750.	3.8	36
123	Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. <i>Clinical Rheumatology</i> , 2009, 28, 371-377.	2.2	10
124	Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 11-14.	1.9	2
125	Managing comorbidity in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 201-205.	1.9	2
126	Access to high cost medicines in Australia: ethical perspectives. <i>Australia and New Zealand Health Policy</i> , 2008, 5, 4.	2.2	7



#	ARTICLE	IF	CITATIONS
127	The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. Australia and New Zealand Health Policy, 2007, 4, 26.	2.2	7
128	Assessing health outcome data on high-cost medicines in Australia. Medical Journal of Australia, 2006, 184, 411-413.	1.7	6
129	Sample size is beside the point in policy development research. Australian and New Zealand Journal of Public Health, 2005, 29, 583.	1.8	4
130	Tailoring access to high cost, genetically targeted drugs. Medical Journal of Australia, 2005, 182, 607-608.	1.7	15